Table 1 Demographic and clinical characteristics of patients at baseline (N = 51)
Characteristic | n (%) |
|---|---|
Age, years | |
Median | 66 |
Range | 35–74 |
ECOG performance status | |
0 | 31 (60.8) |
1 | 10 (19.6) |
2 | 10 (19.6) |
Tumor status | |
Stage IV | 19 (37.3) |
Recurrence | 32 (62.7) |
Status of menopause | |
Premenopause | 8 (15.7) |
Postmenopause | 43 (84.3) |
Histopathological types | |
Common | 49 (96.1) |
Special | 2 (3.9) |
Hormone receptor status | |
ER-positive | 42 (82.4) |
ER-negative | 9 (17.6) |
PgR-positive | 38 (74.5) |
PgR-negative | 13 (25.5) |
Triple-negative (ER, PgR, HER2) | 9 (17.6) |
Pre- or postoperative treatment | |
Anthracycline | 16 (31.4) |
Paclitaxel | 4 (7.8) |
Docetaxel | 12 (23.5) |
Hormone therapy | 27 (52.9) |
Hormone therapy after recurrence | 36 (70.6) |
First-line chemotherapy | 34 (66.7) |
Second-line chemotherapy | |
Anthracycline | 6 (11.8) |
Oral 5-fluorouracil | 11 (21.5) |
Number of metastases | |
1 | 7 (13.7) |
2 | 10 (19.6) |
3 | 13 (25.5) |
4 | 5 (9.8) |
5 | 10 (19.6) |
6–8 | 6 (11.8) |
Dominant site of metastases | |
Visceral | 42 (82.4) |
Nonvisceral | 9 (17.6) |
Site of metastasis | |
Bone | 35 (68.6) |
Liver | 32 (62.7) |
Local lymph node | 27 (52.9) |
Lung | 21 (41.2) |
Local lesion | 17 (33.3) |
Distal lymph node | 15 (29.4) |
Pleural effusion | 10 (19.6) |
Pleura | 6 (11.8) |
Brain | 2 (3.9) |
Contralateral mamma | 2 (3.9) |
Cardiac effusion | 1 (2.0) |
Spleen | 1 (2.0) |
Pulmonary lymphangitis | 1 (2.0) |
Skin | 1 (2.0) |
Adrenal | 1 (2.0) |